| CABOTEGRAVIR; RILPIVIRINE | VIIV Healthcare | ||
| 400MG/2ML;600MG/2ML, 600MG/3ML;900MG/3ML ; SUSPENSION,EXTENDED RELEASE |
Less Than $1000 mn
|
||
| None | None | ||
|
Less Than 5
|
None | ||
| None | None | ||
| CABENUVA, a 2-drug co-packaged product of cabotegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. | |||
|
Yes
| |||
| CABENUVA KIT | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||
| *,*-**(******-)*********(-***)-*-*********** *********** ** *************** ****** | *** ********** *********** *********** | *** ********** *********** *********** | *-[(*,*-**************)******]-*-*******-*-******-*,*-*****-*,*,*,*,**,***-*********[*,*] *******[*,*-*]******[*,*-*]********-*-*********** ****** *** ********* ********** ******** | ******* *********** ** ****** | (**,****)-*-[*,*-**************)******]-*-*******-*-******-*,*-*****-*,*,*,*,**,***-*********[*,*]*******[*,*-*]******[*,*-*]********-*-*********** ****** ** ****-*** ***** | ************** ************ | ************** ************ | **** **** ********* ** ***-********* **** ****** | ****** ***** **** *************** | ******** *** ******** *** ********** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|